China ETFs Bounce as DeMark Foresees Nearly 30% Rally

ETF Trends

One of the worst-performing emerging market ETFs this year, iShares FTSE China 25 (FXI), rebounded more than 2% in early U.S. trading Wednesday after a noted technical analyst predicted a strong rally in Chinese stocks.

The China ETF is down about 10% year to date after the government unveiled new measures designed to cool property prices. Investors are also worried about a potential slowdown in the world’s second-largest economy as well as more central-bank tightening measures.

Earlier this week, JP Morgan (JPM) cut its view on China to underweight and recommended bearish bets against the country’s largest banks. [China Downgraded by JP Morgan After ETF Falls 12%]

However, the Shanghai Composite on Wednesday rallied nearly 3% for its largest gain in over two months after Tom DeMark at Market Studies LLC predicted the index will rally as much as 28% by September, Bloomberg News reports.

In late 2012, DeMark accurately forecasted a rebound in China’s equity market. At the time, he said everyone was negative on Chinese stocks and the bears were exhausted. [ETFs to Access China’s New Growth Phase]

Now, Demark says China will continue its climb following the recent pullback.

“Recent declines have already priced in investors’ more pessimistic view about economic growth,” said Li Jun, a strategist at Central China Securities Co, in the Bloomberg story. “Given that stocks are still not expensive, a rebound is justified.”

DeMark, who specializes in turning points in markets, also correctly predicted a retreat in Chinese stocks last month. We “are identifying a low-risk entry zone just beneath today’s low of the Shanghai Composite which should be a bottom prior to the resumption of the advance,” DeMark said this week, according to the report.

FXI, the China, has fallen below its 200-day exponential moving average.

iShares FTSE China 25

View photo



The opinions and forecasts expressed herein are solely those of John Spence, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.

View Comments (0)